AnaptysBio (ANAB) had its price target raised by Stifel Nicolaus from $56.00 to $85.00. They now have a "buy" rating on the stock.
AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference [Yahoo! Finance]
AnaptysBio (ANAB) had its price target raised by Barclays PLC from $78.00 to $79.00. They now have an "overweight" rating on the stock.
AnaptysBio (ANAB) had its price target raised by HC Wainwright from $51.00 to $66.00. They now have a "buy" rating on the stock.
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]